# CSPC Pharmaceutical Group

Source: https://onco.cc/companies/cspc/  
OnCo record `cspc` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CSPC is a large Chinese pharma whose cancer business rests on albumin-bound paclitaxel and liposomal doxorubicin generics, an ADC pipeline and a growing list of licences to Western companies.

## Summary

Domestic leader in nanoparticle albumin-bound paclitaxel (Keaili) and pegylated liposomal doxorubicin (Duomeisu); innovative pipeline includes the Nectin-4 ADC SYS6002, the Claudin 18.2 ADC SYSA1801, an EGFR ADC and a PD-1 x VEGF programme; licences include an AI-enabled discovery collaboration with AstraZeneca (June 2025) and ADC deals. Illustrates the shift of China's big generic houses into originator research.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Also known as: CSPC; 石药集团; CSPC Ouyi Pharmaceutical Co., Ltd.; CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
- Tags: china
- HQ: Shijiazhuang
- Type: pharma
- Website: https://www.cspc.com.hk/
- Ticker: 1093.HK

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/CSPC_Pharmaceutical_Group
- Official website: https://www.cspc.com.hk/

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Chemotherapy](https://onco.cc/fronts/chemotherapy/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [Farletuzumab-exatecan](https://onco.cc/drugs/farletuzumab-exatecan/), [HB1801](https://onco.cc/drugs/hb1801/), [JMT101](https://onco.cc/drugs/jmt101/), [JMT203](https://onco.cc/drugs/jmt203/), [JSKN003](https://onco.cc/drugs/jskn003/), [KN026](https://onco.cc/drugs/kn026/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pegylated liposomal doxorubicin](https://onco.cc/drugs/pegylated-liposomal-doxorubicin/), [SYS6010](https://onco.cc/drugs/sys6010/), [SYS6023](https://onco.cc/drugs/sys6023/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- trials: [A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer](https://onco.cc/trials/nct06296706/), [A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations](https://onco.cc/trials/nct06735391/), [A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer](https://onco.cc/trials/nct07597629/), [A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer](https://onco.cc/trials/nct07714668/), [A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct07744763/), [A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer](https://onco.cc/trials/nct07750041/), [A Phase III Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC](https://onco.cc/trials/nct07376382/), [A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer](https://onco.cc/trials/nct06747338/), [A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer](https://onco.cc/trials/nct07441460/), [A Study of JMT203 in Patients With Cancer Cachexia](https://onco.cc/trials/nct06868849/), [A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors](https://onco.cc/trials/nct07241936/), [A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous No](https://onco.cc/trials/nct07256509/), [A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct07672223/), [A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in N](https://onco.cc/trials/nct06829459/), [A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)](https://onco.cc/trials/nct06505395/), [Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL](https://onco.cc/trials/nct04668690/), [Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors](https://onco.cc/trials/nct07122063/), [DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer](https://onco.cc/trials/nct06313086/), [Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer](https://onco.cc/trials/nct05838066/), [First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors](https://onco.cc/trials/nct06877650/), [JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations](https://onco.cc/trials/nct06391944/), [JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer](https://onco.cc/trials/nct06846437/), [KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy](https://onco.cc/trials/nct05427383/), [Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Canc](https://onco.cc/trials/nct06571461/), [Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors](https://onco.cc/trials/nct07415863/), [Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors](https://onco.cc/trials/nct07280832/), [Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）](https://onco.cc/trials/nct06927986/), [Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors](https://onco.cc/trials/nct06947291/), [Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors](https://onco.cc/trials/nct07165886/), [Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy](https://onco.cc/trials/nct06957379/), [SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma](https://onco.cc/trials/nct07254585/), [SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNST](https://onco.cc/trials/nct07633873/), [SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase III](https://onco.cc/trials/nct07442565/)

---
JSON: https://onco.cc/api/v1/entities/cspc.json